July 29 - Viehbacher tells Termeer about Sanofi's plan to send a written proposal, including a price per share. The subsequent letter outlined Sanofi's $69 per share offer. August 11 - Termeer sends a letter to Viehbacher saying that Genzyme's board has rejected Sanofi's offer. August 29 - Sanofi publicizes its offer for Genzyme.

-----

PARIS  (Reuters) - Sanofi-Aventis has reached an agreement in principle to acquire Genzyme Corp for about $19.2 billion in cash plus future payments based on the performance of an experimental Genzyme drug, according to two sources with knowledge of the talks.The news on Tuesday caps Sanofi's nearly nine-month pursuit of the U.S. biotech company as it seeks to shore up its revenue in the face of looming drug patent expirations.

-----

Sanofi puts expectations for Lemtrada at $700 million. November 26 - Termeer says in a newspaper interview he is open to a deal linking Genzyme's value to the success of Lemtrada by using a contingent value right (CVR). December 13 - Sanofi extends its tender offer deadline until January 21 and says representatives from both companies have been discussing using a CVR as a way to value Genzyme's Lemtrada.

-----

July 10 - Termeer tells Viehbacher Genzyme's board has discussed a potential transaction with Sanofi, but has decided that it was not the right time to explore such a deal. July 28 - Sanofi's board revisits a proposed transaction with Genzyme. Viehbacher proposes sending Genzyme a letter outlining the terms of an acquisition.

-----

Genzyme publicly rejects the bid a day later. September 20 - Termeer and Viehbacher meet to discuss Sanofi's proposal. Termeer refuses to give guidance on a value for Genzyme and suggests that Sanofi withdraw its offer and consider making contact again in 2011. October 4 - Viehbacher takes Sanofi's offer directly to Genzyme shareholders, in a tender to expire on December 10.
